Table 3 Summary of clinical responses

From: Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

 

Panobinostat dose

Overall

 

10 mg

20 mg

30 mg

40 mg

 

AML (n=29)

 CR/CRi

 

1

1

1

3 (10%)

 PR

1

1

4

 

6 (21%)

 Overall (CR/CRi/PR)

    

9 (31%)

 Resistant

 

4

8

2

14 (48%)

 Not evaluable

  

4

2

6 (21%)

MDS (n=10)

     

 CR

1

1

  

2 (20%)

 Marrow CR (mCR)

1

 

1

 

2 (20%)

 PR

  

1

 

1 (10%)

 Overall (CR/mCR/PR)

    

5 (50%)

 Stable disease

  

1

 

1 (10%)

 Progressive disease

1

 

2

 

3 (30%)

 Not evaluable

  

1

 

1 (10%)

% Major hematologic improvement

 HI-Erythroid

1

1

1

 

3/9 (30%)

 HI-Platelet

  

1

 

1/5 (20%)

 HI-Neutrophil

  

2

 

2/2 (100%)

  1. Abbreviations: AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; HI, hematological improvement; MDS, myelodysplastic syndrome; PR, partial remission.
Back to article page